Mediators of inflammation resolution and vasoactive eicosanoids in gestational diabetes and preeclampsia

aMedical School, University of Western Australia, Royal Perth Hospital Unit

bHarry Perkins Institute for Medical Research, University of Western Australia, Perth, Australia

Correspondence to Anne E. Barden, Professor, Medical School, University of Western Australia. Royal Perth Hospital, Box X2213 GPO, Perth 6847, WA, Australia. Tel: +61 8 9224 0272; fax: +61 8 9224 0246; e-mail: [email protected]

Abbreviations: 10S,17S-DiHDHA, 10S,17Sdihydroxy-docosahexaenoic acid; 14-HDHA, (±)14-hydroxy-docosahexaenoic acid; 17R-RvD1, 17R-Resolvin D1; 17S-HDHA, 17S-hydroxy-docosahexaenoic acid; 18-HEPE, (±)18-hydroxy-eicosapentaenoic acid; 18R-RvE3, 18RResolvin E3; 20-HETE, 20-hydroxy-eicosatetraenoic acid; COX2, cyclooxygenase-2; CYP450, cytochrome P450; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LOX, lipoxygenase; LTB4, leukotriene B4; LXA4, Lipoxin A4; MaR-1, Maresin 1; PD1, Protectin D1; RvD1, Resolvin D1; RvD2, Resolvin D2; RvD2-d5, Resolvin D2-d5; RvD3, Resolvin D3; RvD5, Resolvin D5; RvE1, Resolvin E1; RvE2, Resolvin E2; RvE3, Resolvin E3; SPM, specialised mediators of inflammation resolution

Received 22 February, 2022

Revised 14 June, 2022

Accepted 5 July, 2022

留言 (0)

沒有登入
gif